2022 World Conference on Lung Cancer (ePosters)-EP05.01-002. Real World Treatment Patterns and Outcomes among Unresectable Stage III Non-Small Cell Lung Cancer Patients Initiating Chemoradiotherapy

EP05.01-002. Real World Treatment Patterns and Outcomes among Unresectable Stage III Non-Small Cell Lung Cancer Patients Initiating Chemoradiotherapy

Back to course

Pdf Summary

This document is a summary of a study conducted to analyze real-world treatment patterns and outcomes among patients with unresectable stage III non-small cell lung cancer (NSCLC) who initiated chemoradiotherapy. The study used data sourced from The US Oncology Network's iKnowMed electronic health record system. The study included adults diagnosed with unresectable stage III NSCLC who had at least 2 visits to a US Oncology Network clinic and initiated concurrent chemoradiotherapy (cCRT) during the study period from November 2017 to October 2019.<br /><br />The study found that carboplatin-paclitaxel was the most commonly utilized chemotherapy regimen for patients with stage III NSCLC who initiated cCRT. A significant proportion of patients did not receive durvalumab, an anti-PD-L1 inhibitor, as consolidation therapy in real-world settings. The overall survival was analyzed using the Kaplan-Meier method and showed varying survival probabilities at different time intervals.<br /><br />The study cohort consisted of 959 patients, of which 43.0% received durvalumab post cCRT, while 57.0% were treated with cCRT alone. The median observed follow-up for all patients was 23.6 months. The study acknowledges limitations, including the potential for immortal time bias and the fact that the iKnowMed database is not collected for research purposes.<br /><br />The authors emphasize that real-world practice patterns and outcomes, as well as unmet needs, have not been adequately characterized for patients with unresectable stage III NSCLC since the approval of durvalumab. The study aims to provide insights into the real-world treatment utilization patterns and associated outcomes for this patient population.<br /><br />It is important to note that the document is confidential and the information is copyrighted by Merck & Co., Inc. and its affiliates.

Asset Subtitle

Ashwini Arunachalam

Meta Tag

Speaker Ashwini Arunachalam

Topic Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy

Keywords

unresectable stage III NSCLC

chemoradiotherapy

treatment patterns

outcomes

carboplatin-paclitaxel

durvalumab

consolidation therapy

overall survival

Kaplan-Meier method

real-world settings